Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb;22(2):191-202.
doi: 10.1111/dom.13887. Epub 2019 Nov 5.

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus

Hong Zhang  1 , Xiaoxue Zhu  1 , Xiaojiao Li  1 , Hong Chen  1 , Min Wu  1 , Cuiyun Li  1 , Jingrui Liu  1 , Chengjiao Liu  1 , Yingjun Zhang  2 , Yanhua Ding  1
Affiliations
Randomized Controlled Trial

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus

Hong Zhang et al. Diabetes Obes Metab. 2020 Feb.

Abstract

Aims: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of rongliflozin in a cohort of healthy Chinese people and people with type 2 diabetes mellitus (T2DM).

Materials and methods: We examined the effects of a single ascending dose (SAD) of rongliflozin (10-200 mg) in combination with food (20 mg) in 50 healthy people, and a multiple ascending dose (MAD) of rongliflozin (10-50 mg once daily for 12 days) in 36 people with T2DM.

Results: No serious adverse events (AEs) or discontinuations as a result of AEs (related to rongliflozin) occurred in either study. In healthy participants and those with T2DM, rongliflozin was rapidly absorbed, with a time to maximum plasma concentration of 0.63 to 1.75 hours. Systemic exposure (maximum observed serum concentration and area under the curve) to rongliflozin and its inactive major metabolites (T1444, T1454 and T1830) increased in proportion to dose. In the SAD and MAD studies, there was a dose-related increase in urinary glucose excretion (UGE) ranging from 10 to 50 mg rongliflozin. This increase in UGE was associated with dose-related decreases in serum glucose values in people with T2DM in the MAD group. In the SAD group, UGE plateaued at 50 to 200 mg.

Conclusions: Rongliflozin was well tolerated in all participants. The PK and PD measurements obtained for rongliflozin demonstrate a dose-response relationship when the drug is administered at doses ranging from 10 to 50 mg in healthy people and in people with T2DM.

Keywords: Chinese; SGLT2 inhibitor; clinical trial; pharmacodynamics; pharmacokinetics; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281.
    1. Yang W, Lu J, Weng J, et al. China National Diabetes and metabolic disorders study group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-1101.
    1. Ojha A, Ojha U, Mohammed R, Chandrashekar A, Ojha H. Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus. Clin Pharmacol. 2019;11:57-65.
    1. Sen S, Chakraborty R. Treatment and diagnosis of diabetes mellitus and its complication: advanced approaches. Mini Rev Med Chem. 2015;15(14):1132-1133.
    1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European association for the study of diabetes. Diabetes Care. 2009;32(1):193-203.

Publication types

MeSH terms

LinkOut - more resources